Prime Medicine

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Prime Medicine and other ETFs, options, and stocks.

About PRME

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. 

CEO
Allan Jacob Reine
CEOAllan Jacob Reine
Employees
214
Employees214
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2019
Founded2019
Employees
214
Employees214

PRME Key Statistics

Market cap
844.79M
Market cap844.79M
Price-Earnings ratio
-3.17
Price-Earnings ratio-3.17
Dividend yield
Dividend yield
Average volume
3.57M
Average volume3.57M
High today
$4.73
High today$4.73
Low today
$3.99
Low today$3.99
Open price
$4.01
Open price$4.01
Volume
5.01M
Volume5.01M
52 Week high
$6.94
52 Week high$6.94
52 Week low
$1.11
52 Week low$1.11

Stock Snapshot

The current Prime Medicine(PRME) stock price is $4.66, with a market capitalization of 844.79M. The stock trades at a price-to-earnings (P/E) ratio of -3.17.

On 2026-01-23, Prime Medicine(PRME) stock moved within a range of $3.99 to $4.73. With shares now at $4.66, the stock is trading +16.8% above its intraday low and -1.5% below the session's peak.

Trading volume for Prime Medicine(PRME) stock has reached 5.01M, versus its average volume of 3.57M.

Over the past 52 weeks, Prime Medicine(PRME) stock has traded between a high of $6.94 and a low of $1.11.

Over the past 52 weeks, Prime Medicine(PRME) stock has traded between a high of $6.94 and a low of $1.11.

Analyst ratings

67%

of 12 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own PRME. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.